Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Newly-Formed Arrotex Is Considering Further Deals

Executive Summary

Following the formation of Australia’s Arrotex through the merger of Apotex Australia and former Strides unit Arrow Pharmaceuticals, CEO Dennis Bastas sets out the firm’s priorities as a central player in the Australian market, as well as longer-term plans including potential future deals and reaching beyond Australia and into south-east Asia, in an exclusive interview with Generics Bulletin.

You may also be interested in...



Australia’s Manufacturing Road Map Wins Plaudits From Industry

A medicines manufacturing “road map” set out by Australia’s government has the backing of the local off-patent industry.

People Round-Up: Alvotech Appoints Science Chief As Read Exits Pfizer

Alvotech has brought in a Pfizer biosimilars specialist as chief scientific officer, while Lupin has recruited a women’s health expert to head its US Specialty business. And Ian Read is to retire as Pfizer’s chairman at the start of next year.  

Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate

Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB140536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel